RVMD ▲ +0.4% - Revolution Medicines, Inc.
$RVMD - Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
05-OCT-2026 08:00 AM ET
Share this post
More filings for $RVMD
RVMD - Revolution Medicines, Inc. - SEC Filing Update (05-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 5, 2026RVMD ▲ +13.2% - Revolution Medicines, Inc.Nov 4, 2026RVMD ▲ +10.6% - Revolution Medicines, Inc.Nov 4, 2026RVMD ▲ +12.2% - Revolution Medicines, Inc.Nov 4, 2026RVMD ▲ +12.2% - Revolution Medicines, Inc.Nov 4, 2026RVMD - Revolution Medicines, Inc. - SEC Filing Update (30-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 30, 2026
View full $RVMD filing history →💬 Comments
Loading comments…
Leave a comment